Monte Rosa Therapeutics (GLUE) Gains from Sales and Divestitures (2021 - 2026)
Monte Rosa Therapeutics (GLUE) recorded quarterly Gains from Sales and Divestitures of $186515.0 in Q1 2026, up 66.3% quarter-over-quarter from $112159.0 in Q4 2025.
Monte Rosa Therapeutics (GLUE) Gains from Sales and Divestitures (2021 - 2026) Analysis & Trends
Monte Rosa Therapeutics' Gains from Sales and Divestitures history runs 6 years deep, the most recent figure standing at $186515.0 for Q1 2026.
- In Q1 2026, Gains from Sales and Divestitures changed N/A year-over-year to $186515.0; the TTM figure through Mar 2026 stood at $186515.0 (changed N/A YoY), while the FY2025 annual figure was $112159.0, down 8.09% from the prior year.
- Gains from Sales and Divestitures was $186515.0 for Q1 2026 at Monte Rosa Therapeutics, up from $112159.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $186515.0 in Q1 2026 to a low of $4691.0 in Q1 2024.
- Historically, Gains from Sales and Divestitures has averaged $81833.8 across 5 years, with a median of $85938.0 in 2022.
- The sharpest annual moves came in 2024 and 2025: Gains from Sales and Divestitures slumped 85.87% in 2024, then soared 1095.6% in 2025.
- A 5-year view of Gains from Sales and Divestitures shows it stood at $136058.0 in 2022, then tumbled by 67.95% to $43600.0 in 2023, then surged by 179.89% to $122034.0 in 2024, then declined by 8.09% to $112159.0 in 2025, then surged by 66.3% to $186515.0 in 2026.
- The last three Gains from Sales and Divestitures figures came in at $186515.0 (Q1 2026), $112159.0 (Q4 2025), and $112159.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Monte Rosa Therapeutics | 1.83 Bn | 1.15 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 186,515.00 |
| Mar 31, 2026 | 186,515.00 |
| Dec 31, 2025 | 112,159.00 |
| Dec 31, 2025 | 112,159.00 |
| Sep 30, 2025 | 112,159.00 |
| Sep 30, 2025 | 112,159.00 |
| Jun 30, 2025 | 112,159.00 |
| Jun 30, 2025 | 112,159.00 |
| Dec 31, 2024 | 122,034.00 |
| Dec 31, 2024 | 122,034.00 |
| Sep 30, 2024 | 122,034.00 |
| Sep 30, 2024 | 122,034.00 |
| Jun 30, 2024 | 9,381.00 |
| Jun 30, 2024 | 9,381.00 |
| Mar 31, 2024 | 4,691.00 |
| Mar 31, 2024 | 4,691.00 |
| Dec 31, 2023 | 43,600.00 |
| Dec 31, 2023 | 43,600.00 |
| Sep 30, 2023 | 43,600.00 |
| Sep 30, 2023 | 43,600.00 |